Elicio Therapeutics Announces Proposed Public Offering
BOSTON, June 27, 2024 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq:ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it has commenced an underwritten public offering of its shares of common stock and accompanying common warrants and, in lieu of its shares of common stock to certain investors that so choose, pre-funded warrants to purchase shares of common stock and accompanying common warrants. All of the common stock, pre-funded warrants and accompanying common warrants are being offered by Elicio. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.